NCT04354831View on ClinicalTrials.gov

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

anti-SARS-CoV-2 convalescent plasma

"* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion"

Trial Locations (1)

53226

Froedtert Hospital, Milwaukee

All Listed Sponsors
collaborator

Froedtert Hospital

OTHER

lead

Medical College of Wisconsin

OTHER

NCT04354831 - Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients | Biotech Hunter | Biotech Hunter